BioCentury
ARTICLE | Clinical News

Esperion to raise funds after reporting bempedoic acid LDL-C data

August 9, 2017 12:16 AM UTC

Esperion Therapeutics Inc. (NASDAQ:ESPR) proposed to raise $150 million in a follow-on after market close on Tuesday following its announcement earlier in the day that oral bempedoic acid (ETC-1002)/Zetia ezetimibe plus Lipitor atorvastatin met the primary endpoint of reducing LDL-C compared to placebo in a Phase II trial to treat hypercholesterolemia. The data, which Esperion released during market hours, drove the stock up $6.96 (15%) to $52.13.

By 1Q19, Esperion plans to submit two NDAs to FDA for bempedoic acid as a single agent and for a bempedoic acid/ezetimibe combination pill for an LDL-C lowering indication. The company is planning MAA submissions to EMA for both products in 2Q19...